Immix Biopharma Inc (IMMX) Stock Price, Quote & News

Company Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 310 651 8041

Website: www.immixbio.com

Address:

11400 West Olympic Boulevard, Suite 200, Los Angeles, United States

BiotechGoldenEra May. 13 at 4:02 AM

$IMMX what a year

0 · Reply

OldUsernameIsEmbarassing May. 13 at 1:40 AM

$IMMX

0 · Reply

History101 May. 13 at 12:15 AM

$IMMX up strong on a deep red market day...awesome

0 · Reply

Ivorthedriver May. 12 at 7:48 PM

$IMMX 3000 June $10 puts @ 90 cents! But they won’t take my offer to sell40 of them at same price…ah well. Ivor

1 · Reply

Daddy044 May. 12 at 6:21 PM

$IMMX Buy FN dips!!!!

0 · Reply

mikema1 May. 12 at 5:52 PM

$IMMX breaking out

0 · Reply

mikema1 May. 12 at 2:53 PM

$IMMX Still 3 million shares short as of 4/31. Shorts are trapped.

0 · Reply

Dingalingading May. 12 at 1:42 PM

$IMMX

0 · Reply

Georggggie May. 12 at 1:40 PM

$IMMX

0 · Reply

bnglao24 May. 12 at 12:24 PM

$IMMX Mgt is comparing nxc-201 to Abbvie’s ententamig in the corporate presentation but looks like they should be aware of $REGN linvoseltamab which is slated for an ASCO oral presentation in a few weeks (also a bispecific) https://www.asco.org/abstracts-presentations/268071 Abstract made public next Thursday 👀

2 · Reply

Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

2026-03-30T13:38:42.000Z - 6 weeks ago

Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon

MRK

$Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones$

Mar 30, 2026, 8:45 AM EDT - 6 weeks ago

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

2026-03-30T11:30:46.000Z - 6 weeks ago

Immix Biopharma price target raised to $15 from $14 at Mizuho

2026-03-27T10:16:27.000Z - 6 weeks ago

Immix Biopharma price target raised to $15 from $12 at H.C. Wainwright

2026-03-25T08:55:10.000Z - 7 weeks ago

Immix Biopharma initiated with an Overweight at Morgan Stanley

2026-03-09T08:50:20.000Z - 2 months ago

Immix Biopharma initiated with an Outperform at Citizens

Mar 3, 2026, 8:45 AM EST - 2 months ago

Immix Biopharma to Participate in Upcoming Investor Conferences

2026-02-09T10:40:13.000Z - 3 months ago

Immix Biopharma initiated with an Outperform at Mizuho

2026-01-28T13:50:28.000Z - 3 months ago

Immix Biopharma receives FDA breakthrough therapy designation for NXC-201

Jan 28, 2026, 8:45 AM EST - 3 months ago

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

2026-01-09T22:30:15.000Z - 4 months ago

Immix Biopharma files $750M mixed securities shelf

Dec 9, 2025, 5:45 PM EST - 5 months ago

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

2025-12-09T13:30:52.000Z - 5 months ago

Immix Biopharma price target raised to $12 from $8 at H.C. Wainwright

2025-12-08T11:25:27.000Z - 5 months ago

Immix Biopharma 19.12M share Spot Secondary priced at $5.10

2025-12-08T01:50:12.000Z - 5 months ago

Immix Biopharma announces phase 2 NXC-201 results

Dec 7, 2025, 6:20 PM EST - 5 months ago

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

$At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

Dec 7, 2025, 6:15 PM EST - 5 months ago

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

2025-11-12T13:50:43.000Z - 6 months ago

Immix Biopharma appoints Grabow as Chief Commercial Officer

Nov 12, 2025, 8:45 AM EST - 6 months ago

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

Nov 3, 2025, 8:45 AM EST - 6 months ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Oct 14, 2025, 8:45 AM EDT - 7 months ago

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 6, 2025, 4:05 PM EDT - 7 months ago

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

2025-10-06T12:15:52.000Z - 7 months ago

Immix Biopharma files to sell 6.85M shares of common stock for holders

Oct 1, 2025, 8:45 AM EDT - 7 months ago

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

$Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2$

Sep 18, 2025, 1:30 PM EDT - 8 months ago

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

2025-09-12T10:15:17.000Z - 8 months ago

Immix Biopharma price target raised to $8 from $7 at H.C. Wainwright

2025-09-11T13:35:30.000Z - 8 months ago

Immix Biopharma appoints Nancy Chang to board of directors

Sep 11, 2025, 9:15 AM EDT - 8 months ago

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

2025-09-08T20:20:08.000Z - 8 months ago

Immix Biopharma receives strategic investment from Goose Capital

Sep 8, 2025, 4:05 PM EDT - 8 months ago

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

Aug 25, 2025, 9:30 AM EDT - 9 months ago

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

Aug 6, 2025, 12:30 PM EDT - 9 months ago

Immix Biopharma Announces Other Serious Diseases Strategy

2025-07-11T13:40:51.000Z - 10 months ago

Immix Biopharma announces ‘class-leading’ safety profile for NXC-201

Jul 11, 2025, 9:36 AM EDT - 10 months ago

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

2025-07-07T13:40:34.000Z - 11 months ago

Immix Biopharma announces accelerated NEXICART-2 trial progress

$Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis$

Jul 7, 2025, 9:35 AM EDT - 11 months ago

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Jun 6, 2025, 9:39 AM EDT - 1 year ago

Immix Biopharma Attends FDA CEO Forum in Washington DC

2025-06-03T19:30:19.000Z - 1 year ago

Immix Biopharma files $13.45M common stock ATM offering

Jun 3, 2025, 3:00 PM EDT - 1 year ago

Immix Biopharma Transcript: Status Update

$Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

Jun 3, 2025, 2:55 PM EDT - 1 year ago

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

May 23, 2025, 9:05 AM EDT - 1 year ago

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

$Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

May 22, 2025, 4:02 PM EDT - 1 year ago

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis$

May 21, 2025, 4:03 PM EDT - 1 year ago

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

Apr 23, 2025, 10:04 AM EDT - 1 year ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

$Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis$

Feb 10, 2025, 9:35 AM EST - 1 year ago

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Jan 7, 2025, 9:34 AM EST - 1 year ago

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

$Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis$

Dec 19, 2024, 9:35 AM EST - 1 year ago

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

$Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis$

Dec 16, 2024, 9:48 AM EST - 1 year ago

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

$Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024$

Dec 10, 2024, 9:39 AM EST - 1 year ago

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Dec 9, 2024, 9:33 AM EST - 1 year ago

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

$Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients$

Nov 25, 2024, 9:32 AM EST - 1 year ago

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Oct 2, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Sep 19, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

$Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

Aug 28, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Jul 25, 2024, 9:36 PM EDT - 1 year ago

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Jul 8, 2024, 9:31 AM EDT - 2 years ago

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Jun 17, 2024, 9:35 AM EDT - 2 years ago

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

$Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation$

May 10, 2024, 9:35 AM EDT - 2 years ago

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

Apr 29, 2024, 9:39 AM EDT - 2 years ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Apr 18, 2024, 9:32 AM EDT - 2 years ago

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Apr 15, 2024, 9:36 AM EDT - 2 years ago

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Mar 20, 2024, 9:46 AM EDT - 2 years ago

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Mar 5, 2024, 9:35 AM EST - 2 years ago

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Feb 21, 2024, 9:31 AM EST - 2 years ago

Immix Biopharma 12 Month Review Progress Update

Feb 8, 2024, 4:45 PM EST - 2 years ago

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Feb 7, 2024, 9:37 AM EST - 2 years ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

Feb 5, 2024, 10:30 PM EST - 2 years ago

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Feb 5, 2024, 3:20 PM EST - 2 years ago

Immix Biopharma Announces Proposed Public Offering of Common Stock

Jan 24, 2024, 8:35 AM EST - 2 years ago

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

BiotechGoldenEra May. 13 at 4:02 AM

$IMMX what a year

0 · Reply

OldUsernameIsEmbarassing May. 13 at 1:40 AM

$IMMX

0 · Reply

History101 May. 13 at 12:15 AM

$IMMX up strong on a deep red market day...awesome

0 · Reply

Ivorthedriver May. 12 at 7:48 PM

$IMMX 3000 June $10 puts @ 90 cents! But they won’t take my offer to sell40 of them at same price…ah well. Ivor

1 · Reply

Daddy044 May. 12 at 6:21 PM

$IMMX Buy FN dips!!!!

0 · Reply

mikema1 May. 12 at 5:52 PM

$IMMX breaking out

0 · Reply

mikema1 May. 12 at 2:53 PM

$IMMX Still 3 million shares short as of 4/31. Shorts are trapped.

0 · Reply

Dingalingading May. 12 at 1:42 PM

$IMMX

0 · Reply

Georggggie May. 12 at 1:40 PM

$IMMX

0 · Reply

bnglao24 May. 12 at 12:24 PM

2 · Reply

Fosco_ May. 12 at 9:25 AM

$IMMX FWIW, here's a projected timeline for catalysts and potential stock appreciation (excl. M&A)

4 · Reply

Stock_Catcher May. 12 at 1:47 AM

Treasure Tuesday Watchlist Pt.6 $GSIT $BKKT $VEEE $IMMX $RGTI Crazy Runners Today , Let's Find More Tomorrow

0 · Reply

SillySallySonders May. 12 at 1:39 AM

$IMMX

0 · Reply

ImmxBeliever May. 12 at 1:00 AM

$IMMX quietly tightened the timeline language in the new May corporate deck. March deck: “Final readout” May deck: “Final readout – Topline Q3” That’s not random wording. That’s management narrowing investors toward an expected Q3 catalyst window instead of vague “eventually” language. Also noticeable: * stronger platform positioning * more commercial-stage messaging * upgraded NXC-201 engineering narrative * cleaner institutional presentation overall Feels like transition from “interesting biotech” → “pre-commercial orphan CAR-T story with a defined regulatory path.” The thesis didn’t change. The confidence level did. 🚀

0 · Reply

ImmxBeliever May. 11 at 11:29 PM

$IMMX Some 13Fs. All due by Friday

0 · Reply

Whathehelly May. 11 at 1:39 PM

$IMMX

0 · Reply

bnglao24 May. 11 at 12:24 PM

$IMMX 30 pt update 🚨 No ASCO because they chose ASGCT for the data update. Abstract 👇 https://distribution.us.m-anage.com/from.storage?image=Kn0KAtCjscVNEYTvg0_NV2KkgiKRYl4WQ6G8FgQ8gJddfForKTddaSv3s2alrde00

5 · Reply

Fosco_ May. 11 at 10:53 AM

$IMMX $KYTX Bringing this back to the top for more visibility: In response to @Surfho’s preference for KYTX, I’ve outlined quickly in the pdf link my investment thesis on why I think IMMX offers a better setup . Both very good plays IMO btw.

1 · Reply

InPlay1 May. 11 at 2:20 AM

$IMMX

0 · Reply

InPlay1 May. 11 at 2:19 AM

$IMMX

0 · Reply

stocgurunot May. 11 at 2:11 AM

$IMMX Hello I use Charles Schwab and even though I have had stock since it was $2 Schwab will not let you buy anything off the equity from IMMX. Does anyone know of any brokerage company that will let you use your stock equity of IMMX. Thanks. Pretty ridiculous you could have $500,000 in equity and not be able to buy 1 share of any other stock. (example not me lol)

0 · Reply

StocksPlusStuffers May. 11 at 1:39 AM

$IMMX

0 · Reply

Market Cap	539.76M
Revenue (ttm)	0.00
Net Income (ttm)	-29.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	921,300
Avg Vol	780,896
Day's Range	N/A - N/A
Shares Out	54.41M
Stochastic %K	95%
Beta	0.12
Analysts	Strong Sell
Price Target	$18.25